- Investing.com
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuropathies. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts. As of May 1, 2025, NeuroMetrix, Inc. operates as a subsidiary of electroCore, Inc.
Metrics to compare | NURO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUROPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.9x | −0.5x | |
PEG Ratio | 0.00 | −0.22 | 0.00 | |
Price/Book | 0.0x | 3.3x | 2.6x | |
Price / LTM Sales | 0.0x | 2.6x | 3.3x | |
Upside (Analyst Target) | 0.0% | 22.5% | 43.5% | |
Fair Value Upside | Unlock | 7.0% | 6.8% | Unlock |